McIntyreRSTrakasKLinDBalshawRHwangPRobinsonK, and others. Risk of weight gain associated with antipsychotic treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry2003:48:689–94.
2.
GianfrancescoFWhiteRWangRHNasrallahAH. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry2003:64:847–8.
3.
McIntyreRSMcCannSMKennedySH. Antipsychotic metabolic effects: Weight gain, diabetes and lipid abnormalities. Can J Psychiatry2001:46:273–81.
4.
Health Canada. The growing burden of heart disease and stroke in Canada. Ottawa: Health Canada, May 2003.
5.
RidkerPMRifaiNBuringJECookNR. Comparisons of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Eng J Med2002;347:1557–65.
6.
BoilsonMHamiltonRJ. A survey of monitoring of weight and blood glucose in in-patients. Psychiatr Bull2003;27:424–6.
7.
ArchieSWilsonJHOsborneSHobbsHMcNivenJ.Pilot study: Access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry2003:48:628–32.
